Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "ADC"

210 News Found

Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development
People | November 21, 2024

Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development

Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer


USFDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
Drug Approval | November 16, 2024

USFDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency

Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters


Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2
News | November 13, 2024

Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2

Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds


Pfizer reports Q3 2024 revenue higher by 32% at US$ 17.7 billion
News | November 06, 2024

Pfizer reports Q3 2024 revenue higher by 32% at US$ 17.7 billion

Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion


Jubilant Biosys signs and issues a put option offer to Pierre Fabre Laboratories
News | October 06, 2024

Jubilant Biosys signs and issues a put option offer to Pierre Fabre Laboratories

The acquisition will strengthen the overall company’s position as leading global CRO services partner


AbbVie submits Biologics license application to USFDA for Telisotuzumab Vedotin
Drug Approval | September 28, 2024

AbbVie submits Biologics license application to USFDA for Telisotuzumab Vedotin

Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression


Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial
Clinical Trials | September 09, 2024

Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial

Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients


Ashland completes second expansion of Viatel bioresorbable polymers manufacturing and R&D lab in Ireland
News | August 13, 2024

Ashland completes second expansion of Viatel bioresorbable polymers manufacturing and R&D lab in Ireland

This project is supported by the Irish Government through IDA Ireland